Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation. (PubMed, Transplant Cell Ther) - Jun 7, 2026 - "Valganciclovir offers a cost-effective alternative to letermovir for preventing csCMVi in CMV-seropositive PTCy-based alloHCT recipients, with delayed count recovery precluding initiation as the major constraint for haplo-identical transplantation."
Journal • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
Andrew P Grigg; Andrew Spencer; Ashleigh P Scott; Bianca Cirone; Bradley J Gardiner; C Orla Morrissey; Catelyn Cashion; David J Curtis; David J Gottlieb; James Schwarer; Joanne L Tan; John Coutsouvelis; Louis Do; Matthew J Gleeson; Michael Ashby; Nermen Tawfik; Shafqat Inam; Shaun A Fleming; Shevon Fernando; Shu M Wong; Sushrut S Patil
|